Literature DB >> 18323865

Advances in the molecular biology of malignant mesothelioma.

Shinichi Toyooka1, Takumi Kishimoto, Hiroshi Date.   

Abstract

Malignant mesothelioma (MM) is a highly aggressive tumor with a dismal prognosis. The incidence of MM is increasing as a result of widespread exposure to asbestos. As for the molecular alterations that occur in MM, chromosome alterations including homo-deletion of the P16 and P14 genes located in the 9p21 are well known. Mutations are rare in the P53 and Ras genes, which are frequently present in epithelial solid tumors. However, mutations are frequently present in the neurofibromatosis type 2 gene. Epigenetic alterations including DNA methylation have been found in the MM, the profile of which is different from that of lung cancer, although differential diagnosis is sometimes clinically difficult. As in other malignant tumors, genes that are related to immortalization, proliferation, metastasis, angiogenesis, and anti-apoptosis are also overexpressed in MM, contributing to its malignant phenotype. It is of interest that simian virus 40 has been implicated to be one of the causative factors of MM in western countries. Although the causative role of asbestos is well-known in MM, much less information is available for MM than for other malignant tumors regarding the molecular alterations that occur in the disease. In terms of future tasks, it will be necessary to apply the knowledge that is learned about molecular alterations to clinical practice and to further elucidate the pathogenesis of MM with extensive research.

Entities:  

Mesh:

Year:  2008        PMID: 18323865     DOI: 10.18926/AMO/30990

Source DB:  PubMed          Journal:  Acta Med Okayama        ISSN: 0386-300X            Impact factor:   0.892


  13 in total

1.  DNA copy number gains in malignant pleural mesothelioma.

Authors:  Masashi Furukawa; Shinichi Toyooka; Tatsuro Hayashi; Hiromasa Yamamoto; Nobukazu Fujimoto; Junichi Soh; Shinsuke Hashida; Kazuhiko Shien; Hiroaki Asano; Keisuke Aoe; Kazunori Okabe; Harvey I Pass; Kazunori Tsukuda; Takumi Kishimoto; Shinichiro Miyoshi
Journal:  Oncol Lett       Date:  2015-08-27       Impact factor: 2.967

2.  Cell-growth and migration inhibition of human mesothelioma cells induced by 3-O-methylfunicone from Penicillium pinophilum and cisplatin.

Authors:  Elisabetta Buommino; Anna De Filippis; Rosario Nicoletti; Massimo Menegozzo; Simona Menegozzo; Maria Letizia Ciavatta; Antonietta Rizzo; Virginia Brancato; Maria Antonietta Tufano; Giovanna Donnarumma
Journal:  Invest New Drugs       Date:  2011-06-09       Impact factor: 3.850

3.  Integrated high-resolution array CGH and SKY analysis of homozygous deletions and other genomic alterations present in malignant mesothelioma cell lines.

Authors:  Geula Klorin; Ester Rozenblum; Oleg Glebov; Robert L Walker; Yoonsoo Park; Paul S Meltzer; Ilan R Kirsch; Frederic J Kaye; Anna V Roschke
Journal:  Cancer Genet       Date:  2013-07-05

4.  miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma.

Authors:  Fabian Dominik Mairinger; Robert Werner; Elena Flom; Jan Schmeller; Sabrina Borchert; Michael Wessolly; Jeremias Wohlschlaeger; Thomas Hager; Thomas Mairinger; Jens Kollmeier; Daniel Christian Christoph; Kurt Werner Schmid; Robert Fred Henry Walter
Journal:  Virchows Arch       Date:  2017-05-02       Impact factor: 4.064

Review 5.  Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases.

Authors:  Sarah X L Huang; Marie-Claude Jaurand; David W Kamp; John Whysner; Tom K Hei
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2011       Impact factor: 6.393

6.  hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma.

Authors:  Harvey I Pass; Chandra Goparaju; Sergey Ivanov; Jessica Donington; Michele Carbone; Moshe Hoshen; Dalia Cohen; Ayelet Chajut; Shai Rosenwald; Harel Dan; Sima Benjamin; Ranit Aharonov
Journal:  Cancer Res       Date:  2010-02-16       Impact factor: 12.701

Review 7.  Making the case for molecular staging of malignant pleural mesothelioma.

Authors:  Raphael Bueno
Journal:  Semin Thorac Cardiovasc Surg       Date:  2009

8.  MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53.

Authors:  R F H Walter; F D Mairinger; S Ting; C Vollbrecht; T Mairinger; D Theegarten; D C Christoph; K W Schmid; J Wohlschlaeger
Journal:  Br J Cancer       Date:  2015-02-10       Impact factor: 7.640

9.  microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma.

Authors:  Robert Fred Henry Walter; Claudia Vollbrecht; Robert Werner; Jeremias Wohlschlaeger; Daniel Christian Christoph; Kurt Werner Schmid; Fabian Dominik Mairinger
Journal:  Oncotarget       Date:  2016-04-05

10.  Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy.

Authors:  Robert Fred Henry Walter; Claudia Vollbrecht; Robert Werner; Thomas Mairinger; Jan Schmeller; Elena Flom; Jeremias Wohlschlaeger; Nikolaos Barbetakis; Dimitrios Paliouras; Fotios Chatzinikolaou; Vasilis Adamidis; Kosmas Tsakiridis; Paul Zarogoulidis; Georgia Trakada; Daniel Christian Christoph; Kurt Werner Schmid; Fabian Dominik Mairinger
Journal:  J Cancer       Date:  2016-09-13       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.